Home Blog

0 0

Patent Number: 8,965,089

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Ghosh; Nirmalya (San Bernardino, CA), Ashwal; Stephen (Riverside, CA), Obenaus; Andre (Colton, CA), Bhanu; Bir (Riverside, CA)
Assignee(s): Loma Linda University (Loma Linda, CA) The Regents of the University of California (Oakland, CA)
External link: USPTO website

Abstract:

A method of analyzing a medical image, where the medical image comprises one or more than one region of interest, and where the method comprises a) providing the medical image comprising a set of actual image values; b) rescaling the actual image values to produce corresponding rescaled image values and to produce a rescaled image from the rescaled image values; c) deriving a histogram of the rescaled image values; d) using the histogram to derive an adaptive segmentation threshold; e) using the adaptive segmentation threshold to recursively split the rescaled image; f) terminating the recursive splitting of the sub(sub) images using one or more than one predetermined criteria; and g) identifying one sub(sub) image in the terminated Hierarchical Region Splitting Tree which comprises the region of interest.

0 2

Patent Number: 8,962,912

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Sasgary; Maria (Vienna, AT), Schuster; Maria (Vienna, AT), Schwarz; Hans-Peter (Vienna, AT), Reipert; Birgit Maria (Vienna, AT), Antoine; Gerhard (Vienna, AT), Ehrlich; Hartmut (Vienna, AT)
Assignee(s): Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH)
External link: USPTO website

Abstract:

The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.

0 0

Patent Number: 8,962,556

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Yayon; Avner (Moshav Sitria, IL), Rom; Eran (Rehovot, IL), Chumakov; Irina (Rehovot, IL), Blumenstein; Sara (Ramat Gan, IL)
Assignee(s): Prochon Biotech Ltd. (Ness Ziona, IL)
External link: USPTO website

Abstract:

The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.

0 0

Patent Number: 8,962,555

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): D’Anniballe; Gaetano (L’Aquila, IT), Martin; Franck (L’Aquila, IT), Salvia; Giuseppe (Catania, IT)
Assignee(s): Dompe S.p.A. (L’Aquila, IT) Geymonat S.p.A. (Anagni, IT)
External link: USPTO website

Abstract:

The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.

0 1

Patent Number: 8,962,331

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Wu; Joseph (Palo Alto, CA), Longaker; Michael T. (Stanford, CA), Kay; Mark A. (Stanford, CA), Sung; Ning (Stanford, CA), Jia; FangJun (Stanford, CA), Chen; Zhi-Ying (Shenzhen, CN), Panetta; Nicholas (Pittsburg, PA), Gupta; Deepak (Stanford, CA)
Assignee(s): The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
External link: USPTO website

Abstract:

Human somatic cells are reprogrammed to become induced pluripotent stem cells (iPS cells) by the introduction of a minicircle DNA vector. Cells of interest include adipose stem cells.

0 1

Patent Number: 8,962,324

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Matheny; Robert G (Norcross, GA)
Assignee(s): CorMatrix Cardiovascular, Inc (N/A)
External link: USPTO website

Abstract:

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component and a bioactive agent component. In a preferred embodiment, the ECM scaffold component comprises mesothelial tissue and the bioactive agent comprises a statin.

0 1

Patent Number: 8,962,323

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Soma; Tsutomu (Kanagawa, JP), Yamanishi; Haruyo (Kanagawa, JP)
Assignee(s): Shiseido Company, Ltd. (Tokyo, JP)
External link: USPTO website

Abstract:

The invention provides a method of isolating dermal stem cells, having the steps of subjecting cells separated from the skin by enzyme treatment to suspension culture, and isolating cells positive for stem cell markers from the cultured cells.

0 0

Patent Number: 8,962,322

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Shi; Yanhong (Arcadia, CA), Yip; Man Lun (Honolulu, HI), Li; Wendong (Duarte, CA)
Assignee(s): City of Hope (Duarte, unknown)
External link: USPTO website

Abstract:

Described herein, inter alia, are methods and compositions useful for induced pluripotent stem cell reprogramming.

0 0

Patent Number: 8,962,321

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Kimbrel; Erin Anne (Sudbury, MA), Lanza; Robert (Clinton, MA), Chu; Jianlin (Bedford, MA), Kouris; Nicholas Arthur (Hudson, MA)
Assignee(s): Ocata Therapeutics, Inc. (Marlborough, MA)
External link: USPTO website

Abstract:

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

0 0

Patent Number: 8,962,320

Grant date: December 31, 1969
Priority date: July 30, 2004
Estimated expiration date: July 30, 2024
Inventor(s): Terzic; Andre (Rochester, MN), Behfar; Atta (Rochester, MN)
Assignee(s): Mayo Foundation for Medical Education and Research (Rochester, MN)
External link: USPTO website

Abstract:

This document provides methods and materials for treating cardiovascular tissue. For example, stem cells, compositions containing stem cells, methods for obtaining stem cells, compositions for generating stem cells expressing particular markers, and methods for repairing cardiovascular tissue are provided.